Literature DB >> 22016826

Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Michael R Defee, Zhiqiang Qin, Lu Dai, Jennifer S Isaacs, Chris H Parsons.   

Abstract

Oncogenic viruses are the etiologic agents for a significant proportion of human cancers, but effective therapies and preventative strategies are lacking for the majority of virus-associated cancers. Targeting of virus-induced signal transduction or virus-host protein interactions may offer novel therapeutic strategies for viral cancers. Heat shock protein 90 (Hsp90) is a well-characterized, multifunctional molecular chaperone involved in regulation of signal transduction, transcriptional activation, oncogenic protein stabilization, and neovascularization-pathogenic elements relevant to viral cancer pathogenesis. This review will summarize mechanistic concepts involving regulation of viral oncogenesis by both intracellular and extracellular Hsp90, as well as current therapeutic implications of these data.

Entities:  

Keywords:  KSHV; cancer; heat shock protein; signal transduction; viruses

Year:  2011        PMID: 22016826      PMCID: PMC3195933     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  105 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Authors:  John H Connor; Margie O McKenzie; Griffith D Parks; Douglas S Lyles
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

Review 3.  Development and application of Hsp90 inhibitors.

Authors:  David B Solit; Gabriela Chiosis
Journal:  Drug Discov Today       Date:  2007-11-26       Impact factor: 7.851

4.  Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation.

Authors:  Q Sun; H Matta; G Lu; P M Chaudhary
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

5.  The growth transformation of human B cells involves superinduction of hsp70 and hsp90.

Authors:  R K Cheung; H M Dosch
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

6.  Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Ling Wang; Dirk P Dittmer; Christine C Tomlinson; Farnaz D Fakhari; Blossom Damania
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression.

Authors:  Sathish Sadagopan; Neelam Sharma-Walia; Mohanan Valiya Veettil; Hari Raghu; Ramu Sivakumar; Virginie Bottero; Bala Chandran
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

9.  Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein.

Authors:  Jürgen Beck; Michael Nassal
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

10.  The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway.

Authors:  Christine C Tomlinson; Blossom Damania
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more
  1 in total

1.  Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.

Authors:  Zhongqi Bian; An Xiao; Mingmei Cao; Mingqiu Liu; Shuang Liu; Ye Jiao; Weiyao Yan; Zhongtian Qi; Zhaoxin Zheng
Journal:  Virol J       Date:  2012-11-16       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.